Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Recovery
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Ensitrelvir  COVID-19 treatment studies for Ensitrelvir  C19 studies: Ensitrelvir  Ensitrelvir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
Outcomes in COVID-19 ensitrelvir studies
0 0.5 1 1.5+ All studies 27% 2 255 Improvement, Studies, Patients Relative Risk Viral clearance 35% 2 249 RCTs 27% 2 255 Peer-reviewed 9% 1 227 Early 27% 2 255 Ensitrelvir for COVID-19 c19early.org/en Mar 2023 Favorsensitrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Tau​2 = 0.10, I​2 = 81.4%, p = 0.21 Early treatment 27% 0.73 [0.45-1.19] 0/130 0/125 27% improvement All studies 27% 0.73 [0.45-1.19] 0/130 0/125 27% improvement 2 ensitrelvir COVID-19 studies c19early.org/en Mar 2023 Tau​2 = 0.10, I​2 = 81.4%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.28 Early treatment 9% 0.91 [0.76-1.08] 0/116 0/111 9% improvement All studies 9% 0.91 [0.76-1.08] 0/116 0/111 9% improvement 1 ensitrelvir COVID-19 recovery result c19early.org/en Mar 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.28 Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 32% 0.68 [0.56-0.82] viral time 113 (n) 108 (n) Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Early treatment 35% 0.65 [0.54-0.77] 0/127 0/122 35% improvement All studies 35% 0.65 [0.54-0.77] 0/127 0/122 35% improvement 2 ensitrelvir COVID-19 viral clearance results c19early.org/en Mar 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Tau​2 = 0.10, I​2 = 81.4%, p = 0.21 Early treatment 27% 0.73 [0.45-1.19] 0/130 0/125 27% improvement All studies 27% 0.73 [0.45-1.19] 0/130 0/125 27% improvement 2 ensitrelvir COVID-19 Randomized Controlled Trials c19early.org/en Mar 2023 Tau​2 = 0.10, I​2 = 81.4%, p = 0.21 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.28 Early treatment 9% 0.91 [0.76-1.08] 0/116 0/111 9% improvement All studies 9% 0.91 [0.76-1.08] 0/116 0/111 9% improvement 1 ensitrelvir COVID-19 peer reviewed studies c19early.org/en Mar 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.28 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 36% 0.64 [0.41-1.00] viral load 15 (n) 14 (n) Mukae (DB RCT) 45% 0.55 [0.34-0.90] viral time 15 (n) 14 (n) Mukae (DB RCT) 44% 0.56 [0.35-0.92] viral time 13 (n) 14 (n) Mukae (DB RCT) 54% 0.46 [0.05-4.38] viral+ 1/12 2/11 Mukae (DB RCT) -10% 1.10 [0.22-5.51] viral+ 3/15 2/11 Mukae (DB RCT) 80% 0.20 [0.01-3.80] viral+ 0/13 2/13 Mukae (DB RCT) 54% 0.46 [0.05-4.53] viral+ 1/14 2/13 Mukae (DB RCT) 54% 0.46 [0.10-2.12] viral+ 2/14 4/13 Mukae (DB RCT) 90% 0.10 [0.01-0.85] viral+ 0/15 4/13 Mukae (DB RCT) 80% 0.20 [0.05-0.75] viral+ 2/14 10/14 Mukae (DB RCT) 63% 0.37 [0.15-0.92] viral+ 4/15 10/14 Mukae (DB RCT) 9% 0.91 [0.59-1.40] viral+ 10/14 11/14 Mukae (DB RCT) -10% 1.10 [0.79-1.55] viral+ 13/15 11/14 Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Mukae (DB RCT) 17% 0.83 [0.69-0.99] improv. 114 (n) 111 (n) Mukae (DB RCT) 32% 0.68 [0.56-0.82] viral time 113 (n) 108 (n) Mukae (DB RCT) 44% 0.56 [0.42-0.75] viral time 113 (n) 108 (n) Ensitrelvir COVID-19 outcomes c19early.org/en Mar 2023 Favors ensitrelvir Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit